SGMO Form 3: Nikunj Jain reports 253,003 shares and options
Sangamo Therapeutics (SGMO) director and Principal Accounting Officer Nikunj Jain reported initial beneficial ownership on 10/01/2025.
Rhea-AI Filing Summary
Sangamo Therapeutics (SGMO) director and Principal Accounting Officer Nikunj Jain reported initial beneficial ownership on 10/01/2025. He directly holds 253,003 shares of common stock and multiple stock options exercisable between 10/07/2031 and 02/24/2035, covering a total of 333,454 underlying shares listed in the filing. Several equity awards are time‑based and subject to continued service and standard vesting schedules; some RSUs remain unvested with staggered quarterly vesting through 02/24/2026. The filing was signed by an attorney‑in‑fact on 10/09/2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Jain Nikunj
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 233,454 contracts (Direct);
Common Stock — 253,003 shares (Direct)
Footnotes (4)
- F1. Includes (a) 3,235 shares subject to the Reporting Person's February 24, 2023 restricted stock unit ("RSU") grant that will vest in successive equal quarterly installments through February 24, 2026; (b) 37,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026; and (c) 49,726 shares subject to the Reporting Person's February 25, 2025 RSU grant will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
- F2. One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
- F3. Fully vested
- F4. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What holdings did Nikunj Jain disclose on Form 3 for SGMO?
The filing shows 253,003 shares of common stock directly owned plus stock options that underlie 333,454 additional common shares exercisable through 02/24/2035.
What titles does the reporting person hold at Sangamo (SGMO)?
The form lists the reporting person as a Director and the company's Principal Accounting Officer.
Are any of the reported equity awards unvested and subject to service conditions?
Yes. The filing discloses RSUs and options with staged vesting schedules that require Continuous Service and include vesting through 02/24/2026 for some RSUs.
When do the disclosed options become exercisable or expire?
Exercise/expiration dates for the options in the filing range from 10/07/2031 to 02/24/2035, with specific series listed in the filing and individual exercise prices disclosed.
Who signed the Form 3 and when was it signed?
The filing is signed by Scott B. Willoughby, Attorney‑in‑Fact and dated 10/09/2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
